Cadrenal Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Cadrenal Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a cash flow conversion efficiency ratio of -1.671x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.00 Million) by net assets ($1.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CVKD stock price for real-time trading data and today's change.
Cadrenal Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Cadrenal Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cadrenal Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cadrenal Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Cadrenal Therapeutics, Inc. Common Stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
0.322x |
|
Firefly Neuroscience, Inc.
NASDAQ:AIFF
|
-0.154x |
|
1CM INC.
F:IQ70
|
0.012x |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
0.020x |
|
Jocil Limited
NSE:JOCIL
|
-0.200x |
|
Logisys Inc
KQ:067730
|
0.025x |
|
Telefast Indonesia
JK:TFAS
|
0.023x |
|
S. Pack & Print Public Company Limited
BK:SPACK
|
0.013x |
Annual Cash Flow Conversion Efficiency for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. Review how much free cash does Cadrenal Therapeutics, Inc. Common Stock generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.74 Million | $-12.60 Million | -4.601x | -365.26% |
| 2024-12-31 | $7.44 Million | $-7.36 Million | -0.989x | -115.49% |
| 2023-12-31 | $7.69 Million | $-3.53 Million | -0.459x | -311.46% |
| 2022-12-31 | $-5.55 Million | $-1.20 Million | 0.217x | -- |
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more